1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kuros Biosciences AG

Kuros Biosciences AG

CSBTF
Kuros Biosciences AGUS flagOther OTC
24.75
USD
- -
- -
975.45MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.46
2.84
5.65
0.17
0.06
0.07
0.15
0.17
0.42
0.53
0.92
2.29
- -
3.6
Basic EPS, GAAP
-106.63
-96.7
-226.89
-3.19
-1.88
-1.14
-0.66
-0.47
-0.23
-0.43
-0.28
-0.13
- -
-111.1
Free Cash Flow per Basic Share
-66.63
-67.58
-102.22
-1.44
-1.4
-1.32
-0.64
-0.39
-0.18
-0.23
-0.25
0.06
- -
-69.09
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-926.41
-858.86
-855.49
-6.17
-5.58
-5.31
-3.46
-2.48
-2.98
-3.32
-1.06
-0.75
- -
-965.22
Tangible Book Value per Share
14.63
-74.52
409.52
1.29
0.61
1.09
0.94
1.11
0.64
0.59
0.43
0.72
- -
15.25
Basic Weighted Avg Shares
- -
- -
- -
6
9
10
17
24
33
34
37
37
- -
- -
Sales/Revenue/Turnover
1
1
- -
1
1
1
3
4
14
18
34
85
146
1
Operating Margin (%)
-2,326.6
-1,893.7
-2,931.94
-1,715.27
-2,630.34
-1,919.86
-444.83
-289.16
-63.46
-74.76
-28.66
-6.61
6.13
-2,326.6
Depreciation Expense
- -
- -
- -
1
1
2
3
3
3
3
3
3
3
- -
Net Income, GAAP
-31
-34
-6
-20
-16
-12
-11
-12
-8
-15
-10
-5
3
-31
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
50.91
- -
Profit Margin (%)
-3,082.6
-3,402.6
-4,016.67
-1,860.89
-3,086.89
-1,635.38
-439.36
-285.22
-54.59
-81.15
-30.26
-5.68
1.75
-3,082.5
Working Capital
35
-26
11
10
13
16
20
30
22
19
17
26
41
35
LT Debt
27
- -
- -
- -
- -
- -
2
2
2
1
2
1
1
27
Total Equity
4
-26
10
38
73
76
78
85
77
69
57
64
84
4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.86
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-14.09
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
ST Debt
- -
- -
- -
LT Borrowings
18
19
27
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
Total Current Assets
20
17
40
Cash, Cash Equivalents & STI
18
14
40
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
5
6
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.05%
1.51%
31.14%
Free Cash Flow
-8.08%
-67.73%
-226.54%
Net Income, GAAP
1.78%
-35.31%
-152.76%
Sales/Revenue/Turnover
152.1%
116.81%
71.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
34
2024
- -
- -
- -
- -
85
2025
- -
- -
- -
- -
146

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.28
2024
- -
- -
- -
- -
-0.13
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Christopher T. Fair
Full Time Employees
122
Sector
Healthcare
Industry
Biotechnology
Address
Wagistrasse 25 Schlieren Switzerland 8952
IPO Date
Apr 17, 2014
Website
kuros.ch
Similar Companies
TuHURA Biosciences, Inc. (HURA)
Cyteir Therapeutics, Inc. (CYT)
Genomictree Inc. (228760.KQ)
CSL Limited (CSL.AX)
LianBio (LIANY)
Can-Fite BioPharma Ltd. (CANF)
Business
Kuros Biosciences AG (CSBTF), a Swiss-headquartered biotechnology company founded in 1995, develops and commercializes biologic technologies for musculoskeletal bone healing and tissue regeneration, with a focus on orthobiologics including synthetic bone grafts for spine, extremities, trauma and oncology applications. The company offers MagnetOs Granules, an advanced bone graft featuring submicron needle-shaped NeedleGrip surface technology that promotes bone formation; MagnetOs Putty, a moldable product for filling bony voids in intervertebral disc spaces or posterolateral spine fusions; and Attrax, a biphasic calcium phosphate graft mimicking cancellous bone structure; alongside a legacy portfolio of other tissue repair products. Kuros Biosciences operates in over 20 commercial markets across five continents, primarily in the United States and Europe, targeting orthopedic surgeons and healthcare providers with evidence-based solutions backed by Level I clinical data from initiatives such as Project Fusion. In January 2025, Kuros Biosciences USA Inc., a wholly owned subsidiary, entered a five-year exclusive strategic sales agency agreement with Medtronic's spinal division for MagnetOs products in specified U.S. spine geographies, evolving from a successful pilot and driving rapid revenue growth including a 149% increase in direct MagnetOs sales to CHF 50.6 million in the first nine months of 2024. The company established new U.S. headquarters in Atlanta to support domestic expansion, received FDA IND approval for Fibrin-PTH in spinal fusion, reported a 77% year-over-year revenue increase for the first nine months of 2025, and increased its full-year 2025 guidance amid manufacturing capacity expansions.

Company News

APIChat

  • globenewswire.com

    Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

  • globenewswire.com

    Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

  • seekingalpha.com

    Kuros Biosciences AG (CSBTF) Q4 2025 Earnings Call Transcript